Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis
NCT03274076Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Sep 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by University of Michigan. Started Sep 2017; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03274076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274076.